Persea is a French biotech developing a game-changing treatment against liver cancers: BioTrojan.

The project originates in the encounter of 2 Inserm Researchers, Isabelle de Waziers (Phd) and Pr Philippe Beaune who had been on a reseach programm about the enzym CYP2B6 against cancer since 15 years, and of 2 MDs in Interventional Radiology: Pr Marc Sapoval (APHP, Paris) and Pr Olivier Pellerin (APHP, Paris, CMO).

Persea was founded in 2021 with 2 additional competencies: CGT industrialization (Gisèle Deblandre, Phd, CTO) and business (Sophie de Ferrières, CEO).

BioTrojan is a Cell and Gene Therapy composed of allogeneic mesenchymal stem cells increasing the tumor sensibility to chemotheray. It destroys 100% of the tumor and induces an immune response preventing against tumor recurrence.

Competitive advantages: 1st treatment that cures hepatocarcinoma when not eligeable to surgery + protects against recurrence | industrializable with limited production costs because it is allogenic | is aimed at a large number of patients (no selection via companion test necessary) | platform approach with extension of indication to other solid cancers starting with liver metastases.

–  Therapeutic areas: Solid cancers, liver cancers

–  Based in: Paris (FRANCE)

–  Employees: 1 – 10

– Created in: 2021